
A new study by researchers from the Centers for Disease Control and Prevention and the University of Colorado adds more confusion to the question of when HIV-positive people should start antiretroviral therapy. Although most physicians now hold off on prescribing the drugs until their HIV patients have low CD4-cell counts or very high HIV viral loads, the new study says that starting treatment earlier produces better long-term results.
The study showed that AIDS-related deaths, incidence of HIV-related opportunistic infections, and adverse drug-related side effects were all lower in patients who started treatment when their immune systems were still intact.
"Earlier was better in almost everything we looked at," Kenneth Lichtenstein of the University of Colorado told Reuters Health. "If you stayed on treatment and started earlier, you had the best outcomes."
Current guidelines recommend delaying anti-HIV drug treatment until CD4-cell counts drop below 350 cells per milliliter of blood, HIV viral levels climb above 100,000, or both. Many even wait until CD4-cell counts drop below 200, the clinical threshhold for an AIDS diagnosis. The delay is mostly to avoid drug-related toxicities for as long as possible, say researchers. But Lichtenstein’s study of more than 2,300 HIV patients from eight U.S. cities found that those who started antiretroviral therapy with CD4-cell counts above 350 were 60% less likely to experience such toxicity issues as kidney problems and lipoatrophy and 30% less likely to develop peripheral neuropathy as those who started treatment with CD4-cell counts of 200 or lower.
The researchers say their findings show there is no reason to delay starting antiretroviral treatment or to delay being tested for HIV to catch infection in its earliest stages. (Advocate.com)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.